Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||27 June 2015|
|PDF File Size:||4.99 Mb|
|ePub File Size:||5.60 Mb|
|Price:||Free* [*Free Regsitration Required]|
Trials with results Trials without results. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. Restricciones de tratamientos previos: Combination product that includes a device, but does not involve an Advanced Therapy.
EU Clinical Trials Register. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Committee on Advanced therapies CAT has issued a classification l-aspadaginasa this product. Trials with results Trials without results Clear advanced search filters. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.
The duration of this interval must be approved by the Onyx study medical monitor. The trial involves single site in the Member State concerned.
l-asparaginasa efectos adversos pdf – PDF Files
Active treatment for graft-versus-host disease 6. Known allergy advetsos Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy?
Both Female Only Male Only. IMP with orphan designation in the indication. Age 18 years or younger at the time of study treatment initiation. For these items you should use the filters and not add them to your search terms in the text field.
Subjects must have a serum creatinine level that is? Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.
Review by the Competent Authority or Ethics Committee in the country concerned. Date on which this record was first entered in the EudraCT database:. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib advrrsos combination with induction chemotherapy.
Subjects are under 18 years old. Cancer AND drug name. Known allergy to any of the drugs used in the study.
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Karnofsky or Lansky scores?
l-asparaginasa efectos adversos pdf
Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Adequate liver function, defined as both of the following: Pneumonia AND sponsor name. Clear advanced search filters. The IMP has been designated in this indication as an orphan drug in the Community. Title of the trial for lay people, in easily understood, i. How to search [pdf]. Relapsed or Refractory Acute Lymphoblastic Leukemia.